Lindvall-Axelsson M, Nilsson C, Owman C, Winbladh B
Department of Medical Cell Research, University of Lund, Sweden.
Exp Neurol. 1992 Mar;115(3):394-9. doi: 10.1016/0014-4886(92)90204-4.
Omeprazole, a specific inhibitor of H(+)-K(+)-activated ATPase, gave a dose-dependent inhibition of CSF production as determined by cerebroventriculocisternal perfusions in the rabbit. The reduction was 35% when the perfusate concentration of omeprazole was 10(-6) M and 25% after an intravenous dose of 0.2 mg/kg of omeprazole, respectively. A similarly substituted benzimidazol (H178/42) without H(+)-K(+)-ATPase-inhibiting properties did not affect CSF production at a perfusate concentration of 10(-5) M. Omeprazole in a concentration of 2 x 10(-4) M and more caused a significant but variable reduction in total and Na(+)-K(+)-ATPase activity in choroid plexus homogenates. However, in concentrations of 2 x 10(-5) M and less, no effect on total or Na(+)-K(+)-ATPase activity was obtained. Nor did omeprazole (2 x 10(-4) M) influence HCO3-ATPase. Choline uptake in isolated choroid plexus was significantly reduced by 86% in the presence of acid-pretreated omeprazole 2 x 10(-3) M, but was not affected by 2 x 10(-5) M omeprazole (intact or acid-pretreated). Thus, the mechanism for the marked inhibitory influence of omeprazole on CSF production is not yet evident. In doses causing even a 50% reduction of CSF production, no side effects were observed in contrast to Na(+)-K(+)-ATPase inhibitors such as ouabain.
奥美拉唑是一种H(+)-K(+)-激活的ATP酶的特异性抑制剂,通过兔脑室池灌注法测定,它对脑脊液生成有剂量依赖性抑制作用。当灌注液中奥美拉唑浓度为10(-6) M时,脑脊液生成减少35%;静脉注射0.2 mg/kg奥美拉唑后,减少25%。一种没有H(+)-K(+)-ATP酶抑制特性的类似取代苯并咪唑(H178/42)在灌注液浓度为10(-5) M时不影响脑脊液生成。浓度为2×10(-4) M及更高的奥美拉唑会使脉络丛匀浆中的总ATP酶和Na(+)-K(+)-ATP酶活性显著但可变地降低。然而,浓度为2×10(-5) M及更低时,对总ATP酶或Na(+)-K(+)-ATP酶活性没有影响。奥美拉唑(2×10(-4) M)也不影响HCO3-ATP酶。在存在2×10(-3) M酸预处理的奥美拉唑时,分离的脉络丛中的胆碱摄取显著降低了86%,但不受2×10(-5) M奥美拉唑(完整或酸预处理)的影响。因此,奥美拉唑对脑脊液生成的显著抑制作用机制尚不清楚。与哇巴因等Na(+)-K(+)-ATP酶抑制剂相比,即使在导致脑脊液生成减少50%的剂量下,也未观察到副作用。